mTOR treatment in lymphangioleiomyomatosis: the role of everolimus

References

• Henske EP, McCormack FX. Lymphangioleiomyomatosis – a wolf in sheep’s clothing. J Clin Invest. 2012 Nov;122(11):3807–3816.
   PubMed Web of Science ®Google Scholar
• Miyake M, Tateishi U, Maeda T, et al. Pulmonary lymphangioleiomyomatosis in a male patient with tuberous sclerosis complex. Radiat Med. 2005 Nov;23(7):525–527.
   PubMedGoogle Scholar
• Adriaensen ME, Schaefer-Prokop CM, Duyndam DA, et al. Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex. Clin Radiol. 2011 Jul;66(7):625–628.
   PubMed Web of Science ®Google Scholar
• Johnson SR, Cordier JF, Lazor R, the Review Panel of the ERS LAM Task Force. European respiratory society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010;35:14–26.
   PubMed Web of Science ®Google Scholar
• Glasgow CG, Steagall WK, Taveira-DaSilva A, et al. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med. 2010;104:SS45-S58.
   Google Scholar
• Mavroudi M, Zarogoulidis P, Katsikogiannis N, et al. Lymphangioleiomyomatosis: current and future. J Thorac Dis. 2013;5(1):74–79.
   PubMed Web of Science ®Google Scholar
• Crino PB, Nathanson KL, Henske E, The tuberous sclerosis complex. N Engl J Med. 2006;355:1345–1356.
   PubMed Web of Science ®Google Scholar
• Bourneville D. Sclérose tubéreuse des circonvolutions cérébrales: Idiotie et épilepsie hemiplégique. Archives De Neurologie, Paris (In French). 1880;1:81–9l.
   Google Scholar
• Lutembacher R. Dysembryomes metatypiques des reins; carcinose submiliaire aigue du poumon avec emphyseme generalise et double pneumothorax. Ann Med. 1918;5:435–450.
   Google Scholar
• Von Stossel E. Uber muskulare Cirrhose der Lunge. Beitr Klin Tuberk. 1937;90:432–442.
   Google Scholar
• Corrin B, Averill A, Liebow A,MD, et al. Pulmonary lymphangioleiomyomatosis. Am J Pathol. 1975;79:347–382.
   Google Scholar
• Cornog JL, Enterline HT. Lymphangiomyoma, a benign lesion of chyliferous lymphatics synonymous with lymphangiopericytoma. Cancer. 1966 Dec;19:1909–1930.
   PubMed Web of Science ®Google Scholar
• Martignoni G, Pea M, Reghellin D, et al. PEComas: the past, the present and the future. Virchows Arch. 2008 Feb;452(2):119–132.
   PubMed Web of Science ®Google Scholar
• Martignoni G, Pea M, Reghellin D, et al. Molecular pathology of lymphangioleiomyomatosis and other perivascular epithelioid cell tumors. Arch Pathol Lab Med. 2010 Jan;134(1):33–40.
   PubMed Web of Science ®Google Scholar
• Johnson SR. The ERS guidelines for LAM: trying a rationale approach to a rare disease. Respir Med. 2010;104:SS33-S41.
   Google Scholar
• Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013 October;49:255–265.
   PubMed Web of Science ®Google Scholar
• Almoosa KF, Ryu JH, Mendez J, et al. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. Chest. 2006;129:1274–1281.
   PubMed Web of Science ®Google Scholar
• Ryu JH, Doerr CH, Fisher SD, et al. Chylothorax in lymphangioleiomyomatosis. Chest. 2003;123:623–627.
   PubMed Web of Science ®Google Scholar
• Matsui K, Takeda K, Yu Z-X, et al. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioliomyomatosis. Arch Pathol Lab Med. 2000;124:267–275.
   PubMed Web of Science ®Google Scholar
• Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med. 2006;354:2621–2622.
   PubMed Web of Science ®Google Scholar
• Pimenta SP, Baldi BG, Acencio MM, et al. Doxycycline use in patients with lymphangioleiomyomatosis: safety and efficacy in metalloproteinase blockade. J Bras Pneumol. 2011;37:424–430.
   PubMed Web of Science ®Google Scholar
• Chang WY, Cane JL, Kumaran M, et al. A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis. Eur Respir J. 2014 Apr;43(4):1114–1123.
   PubMed Web of Science ®Google Scholar
• Algar J. Novartis Working on ‘Fountain of Youth’ Drug. Tech Times; 2015 Dec 26. Available from: www.Techtimes.com
   Google Scholar
• Curatolo P, Moavero R, De Vries P. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015;14:733–745.
   PubMed Web of Science ®Google Scholar
• Kirchner GI, Meier-Wiedenbach I, Manns M. Clinical pharmacokinetics of everolimus. Clin Pharmacol. 2004;43(2):83–95.
   Google Scholar
• Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358:140–151.
   PubMed Web of Science ®Google Scholar
• Franz D, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125–132.
   PubMed Web of Science ®Google Scholar
• Koenig MK, Hebert AA, Roberson J, et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs R D. 2012 Sep 1;12(3):121–126.
   PubMedGoogle Scholar
• Franz D, Belousova E, Sparagana S, et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2 year open label extension of the randomised EXIST-1 study. Lancet Oncol. 2014;15(13):1513–1520.
   PubMed Web of Science ®Google Scholar
• McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364:1595–1606.
   PubMed Web of Science ®Google Scholar
• Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest. 2011 Apr;121(4):1231–1241.
   PubMed Web of Science ®Google Scholar
• Mackeigan JP, Krueger DA. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro-Oncology. 2015;0:1–10.
   Google Scholar
• Somers MJ, Paul E. Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation. J Clinical Pharmacol. 2015;55(4):368–376.
   PubMed Web of Science ®Google Scholar
• Casciano R, Chulikavit M, Di Lorenzo G, et al. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib. Value in Health. 2011;14(6):846–851.
   PubMed Web of Science ®Google Scholar
• Morton JM, McLean C, Booth SS, et al. Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment. J Heart Lung Transplant. 2008;27:462–465.
   PubMed Web of Science ®Google Scholar
• Sugimoto R, Nakao A, Yamane M, et al. Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation. J Heart Lung Transplant. 2008;27:921–924.
   PubMed Web of Science ®Google Scholar
• Ohara T, Oto T, Miyoshi K, et al. Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis. Ann Thorac Surg. 2008;86:e7-8.
   PubMed Web of Science ®Google Scholar
• Faehling M, Frohnmayer S, Leschke M, et al. Successful pregnancy complicated by persistent pneumothorax in a patient with lymphangioleiomyomatosis (LAM) on sirolimus. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):153–155.
   PubMed Web of Science ®Google Scholar
• Neurohr C, Hoffmann AL, Huppmann P, et al. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis? Respir Res. 2011;12:66.
   PubMed Web of Science ®Google Scholar
• Casanova A, Giron RM, Acosta O, et al. Lymphangioleiomyomatosis treatment with sirolimus. Arch Bronconeumol. 2011;47(9):470–472.
   PubMed Web of Science ®Google Scholar
• Montero MA, Roman A, Berastegui C. Radical reduction of smooth muscle cells in explanted lung of a LAM patient treated with sirolimus: first case report. J Heart Lung Transplant. 2012;31(4):439–440.
   PubMed Web of Science ®Google Scholar
• Bujalance-Cabrera C, Vaquero-Barrios JM, Redel-Montero J, et al. Reduction in size of renal angiomyolipoma after treatment with everolimus in lung transplantation due to lymphangioleiomyomatosis. Arch Bronconeumol. 2012;48:479–481.
   PubMed Web of Science ®Google Scholar
• Mohammadieh AM, Bowler SD, Silverstone E, et al. Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis. Med J Aust. 2013;199(2): 121–123.
   PubMed Web of Science ®Google Scholar
• Barrera P, Simons SO, Luijk B, et al. Efficacy of sirolimus therapy for chylous effusions in lymphangioleiomyomatosis. Ann Am Thorac Soc. 2013;10(4):408–409.
   PubMedGoogle Scholar
• Paika HM, Arriaga YE, Setiawan A. A case report on the effect of everolimus in renal angiomyolipoma associated with tuberous sclerosis complex. J Med Cases. 2014;5(3):129–136.
   Google Scholar
• Avdeev S, Makarova M, Merzhoeva Z, et al. Treatment with low-dose everolimus in patients with sporadic lymphangioleiomyomatosis (LAM). Abstract. ERS; 2014;44(58). ISSN 0903-1936. Online ISSN 1399–3003.
   Google Scholar
• Hussein M, Aljehani YM, Nizami I, et al. Successful management of bilateral refractory chylothorax after double lung transplantation for lymphangioleiomyomatosis. Ann Thorac Med. 2014;9(2):124–126.
   PubMed Web of Science ®Google Scholar
• Erdélyi T, Bohács A, Vincze K, et al. Successful tacrolimus therapy extended by everolimus in retroperitoneal angiomyolipoma after lung transplantation: a case report. Case Rep Clin Med. 2014;3:636–638.
   Google Scholar
• Koisumi Y, Nagase H, Esaki T. et al. A Case Of TSC - LAM Treated By Everolimus: Improvement In FEV1 And Findings Of Forced Oscillation Technique. ATS; 2015.
   Google Scholar
• Ellender CM, Williams TJ, Gooi J, et al. Management of refractory chylothorax in pulmonary lymphangioleiomyomatosis. Respirol Case Rep. 2015 Jun;3(2):72–74.
   PubMedGoogle Scholar
• Davies DM, De Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011 Jun 15;17(12):4071–4081.
   PubMed Web of Science ®Google Scholar
• Taveira-DaSilva AM, Hathaway O, Stylianou M, et al. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med. 2011;154(12):797–805.
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013 Mar 9;381(9869):817–824.
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for renal angiomyolipoma in patient with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized trial. Nephrol Dial Transplant. 2015;0:1–9.
   Google Scholar
• Goldberg H, Harari S, Cottin V, et al. Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. Eur Respir J. 2015;46(3):783–794.
   PubMed Web of Science ®Google Scholar